CSI Market
Sign In | Register

Akcea Therapeutics Inc (AKCA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AKCA Annual Cash Flow →
Cash flow data covering Akcea Therapeutics Inc–Jun 30 2019 offers a view into how Jun 30 2020's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2020)
6 Months 		(Mar 31 2020) (Dec 31 2019) (Sep 30 2019) (Jun 30 2019)
Operating Activities
Income-92.43
Depreciation & amortization0.42
Amortization of Other Assets2.92
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-2.42
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation23.40
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Licenses-
Non Cash Interest Expense For Line Of Credit Related Party-
Non Cash Sublicensing Expense-
Increase Decrease In Contracts Receivable Net-
Increase Decrease In Contract With Customer Asset-
Increase Decrease In Prepaid Amounts To Related Party-
Operating Lease Right Of Use Asset Amortization-
Operating Lease Right Of Use Asset Amortization Expense0.45
Increase Decrease In Contract With Customer Liability-1.90
Income taxes-0.89
Losses/ -gains on Investments net0.00
Accounts Receivable-8.48
Increase (Decrease) in Accounts Payable-6.00
Increase (Decrease) in Accrued Liabilities0.58
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-2.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities8.84
Discontinued operations0.00
Net Cash flow from Operating Activities-77.53
Investing Activities
Capital Expenditures-0.56
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities118.64
Payments to Acquire Available-for-sale Securities, Debt-215.33
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-97.25
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.65
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-309.36
Proceeds From Stock Options Exercised And Employee Stock Purchase Issuances-
Capital Expenditures Incurred But Not Yet Paid0.04
Noncash Or Part Noncash Acquisition Fixed Assets Acquired-
Noncash Or Part Noncash Acquisition Intangible Assets Acquired-
Unpaid Deferred Offering Costs-
Proceeds From Issuance Or Sale Of Equity To Related Party-
Distributions To Affiliates-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents309.25
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.57
Effect of exchange rate on cash flow0.08
Discontinued operations0.00
Free Cash Flow-78.09
Total Cash Flow-171.12
4 historic quarters locked

Sign in to unlock the full Akcea Therapeutics Inc cash flow history.

Sign In Create Free Account

About AKCA Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.